spacer
home > pmps > winter 2019 > from governance to provenance
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

From Governance to Provenance

Imagine a world where all medical supplies can be traced back to their original source: a world where one can find out exactly where they were manufactured, packaged, and delivered. Picture being able to see its journey through the supply chain: whenever it had been touched, the temperature it was kept at, and whether it was damaged in transit. Just imagine if the item became infected with an airborne disease and the retailer it was purchased from could contact the enduser directly to recall the product and prevent consumption. In an era where the consumer appetite to understand the provenance of products has reached fever pitch, this futuristic utopia sounds as expensive as it does implausible, except it is not – it is well within reach. The ability to deliver it using affordable track and trace technology promises to transform the supply chain not only for medicines, devices, and pharmaceuticals, but also for perishable food and groceries and just about everything else. Welcome to so-called tomorrow’s world, where many of these benefits are achievable today. It is time to deliver them.

Chain Reaction

The supply chain is evolving. Traditionally, the function has focussed on answering two basic questions: ‘where is my product?’ and ‘when is it going to arrive?’ However, this narrow focus has typically been blighted by information black holes where answering these questions is impossible. This lack of visibility has driven huge operational inefficiencies that manifest themselves in excess inventory, extended lead times, and excessive costs for expedited forms of transportation. Blind spots in the supply chain can also lead to other nasty surprises, such as the product arriving either incorrect or substandard because it has not been effectively monitored or managed throughout its journey. These failings have a damaging impact on profitability, customer experience, and long-term brand loyalty.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Chris Sultemeier brings over 30 years of leadership experience in supply chain operations to rfxcel. Chris was the Executive Vice President of Logistics at Walmart, as well as the President and CEO of Walmart Transportation. During his tenure, he was responsible for all domestic and global distribution and fulfilment. Chris received the prestigious Sam M Walton Entrepreneur of the Year Award for his efforts on sustainability. He also serves as an instructor at the Massachusetts Institute of Technology’s Master’s Degree programme for supply chain/logistics/ transportation, US.
spacer
Chris Sultemeier
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement